Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Vita 34 International AG    V3V   DE000A0BL849

News SummaryMost relevantAll newsSector newsTweets 

Vita 34 International AG : Vita 34 AG pursues growth strategy by taking over the majority stake in Stellacure

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2014 | 05:53pm CEST

Vita 34 AG pursues growth strategy by taking over the majority stake in Stellacure

- Vita 34 takes over 75.24 percent of the shares in Stellacure GmbH

- Further strengthening of market leadership in German-speaking area by take-over

- Future growth potential by establishing a second location in Germany

Leipzig, 7 January 2014 - Vita 34 AG (WKN A0BL84), trailblazer of the umbilical cord blood storage in Europe and specialist in cryo-preservation, takes over the majority stake in the umbilical cord blood bank Stellacure GmbH. Through the application, which was already made, and the registration in the Commercial Registry, which is expected in January 2014, Vita 34 will take over 75.24 percent of the Stellacure shares. Both parties agreed not to disclose the sales price. With this take-over, Vita 34 acquires an established brand in the sector of Vita 34 private umbilical cord blood banking and thus pursues the aspect of the growth strategy of further expanding its own share in the German market.

The Stellacure GmbH was founded in Hamburg and Frankfurt in 2006 in cooperation with the Blood Transfusion Service Baden-Württemberg-Hesse of the German Red Cross (DRK). The operating activities of the Stellacure GmbH include the extraction and processing of umbilical cord blood allowing for the highest quality and safety standards. The cord blood is stored at Stellacure's facility located in the building of the DRK Blood Transfusion Service in Frankfurt on the Main. In addition to storages from Germany, Stellacure furthermore works on the Italian and Spanish markets. The team comprises specialists in transfusion and laboratory medicine as well as experienced experts such as biologists, chemists, biotechnologists, and engineers. Being the fourth eldest provider of umbilical cord blood storage services in Germany, Stellacure produced a turnover of about 0.4 million Euros in the fiscal year 2012.

Dr. André Gerth, CEO of Vita 34 AG: 'We are the market leader in the entire German-speaking area with more than 98,000 stored stem cell preparations. Our ambition is to strengthen this dominant position in a sustainable way. We currently see a growing tendency to consolidation on the market of private umbilical cord blood banking. This process provides us as the market leader with considerable opportunities to gain additional market shares. By taking over the majority of Stellacure, we now have a second location in Germany besides Leipzig, based on which we are able to establish a purposeful regional distribution and thus intensify the contact with our relevant target group.'

Company profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and as a full-service provider takes care of the collection logistics, processing, and storage of umbilical cord blood and umbilical cord tissue. Its successful operation is based on an excellent position in the technological segment of cryo-preservation. Cells and tissue are kept alive at temperatures around minus 190 degrees Celsius and can be applied in medical therapies if required. Parents of more than 98,000 children already make use of this offer and have taken provisions for their children by means of a stem cell depot at the company from Leipzig.

07.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
03/23 DGAP-AFR : Vita 34 AG: Vorabbekanntmachung über die Veröffentlichung von Finanzb..
03/23 DGAP-AFR : Vita 34 AG: Preliminary announcement of the publication of financial ..
03/13 VITA 34 INTERNATIONAL : AG Achieves Strongest Growth Since 2010
03/13 DGAP-NEWS : Vita 34 AG Achieves Strongest Growth Since 2010
03/13 DGAP-NEWS : Vita 34 AG erreicht stärkstes Wachstum seit 2010
02/01 VITA 34 INTERNATIONAL : AG increased its turnover in 2016 by 14 per cent in comp..
02/01 DGAP-NEWS : Vita 34 AG increased its turnover in 2016 by 14 per cent in comparis..
02/01 DGAP-NEWS : Vita 34 AG steigert 2016 den Umsatz um 14 Prozent im Vergleich zum V..
01/30 DGAP-PVR : Vita 34 AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der ..
01/30 DGAP-PVR : Vita 34 AG: Release according to Article 26, Section 1 of the WpHG w..
More news
Sector news : Healthcare Facilities & Services - NEC
03/07 Drugmaker shares slip as Trump tweets about pricing system
02/23DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare Swings to Net Loss in 4th Quarter..
02/23DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare Swings to Loss in 4th Quarter
02/22DJFRESENIUS MEDICAL CARE : Profit Lifted by Strong U.S. Performance
02/21 HSBC pulls FTSE lower
More sector news : Healthcare Facilities & Services - NEC
Duration : Period :
Vita 34 International AG Technical Analysis Chart | V3V | DE000A0BL849 | 4-Traders
Full-screen chart
Technical analysis trends VITA 34 INTERNATI...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
André Gerth Chief Executive Officer & IR Contact
Hans-Georg Giering Chairman-Supervisory Board
Falk Neukirch Chief Financial Officer & IR Contact
Holger Födisch Member-Supervisory Board
Alexander Starke Vice Chairman-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HCA HOLDINGS INC16.24%31 873
LABORATORY CORP. OF AM..10.61%14 527
DAVITA INC4.00%12 993
More Results